Xianju Pharmaceutical: About the 2026 remuneration plan for directors and senior managers
Securities code: 002332 Securities abbreviation: Xianju Pharmaceutical Announcement number: 2026-013
Zhejiang Xianju Pharmaceutical Co., Ltd.
About the 2026 remuneration plan for directors and senior management
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
In accordance with the provisions of the "Articles of Association", "Company Directors and Senior Management Remuneration Management System" and other regulations, combined with the company's actual operating and development conditions, and with reference to the salary levels of the industry and surrounding areas, this plan is specially formulated. The details are as follows:
1. Applicable objects
Company directors and senior managers.
2. Applicable period
The application period of this plan is 2026. If there are major changes during the implementation period, the plan can be adjusted according to the company's needs and in strict accordance with the prescribed review process.
3. Salary plan
- Remuneration plan for company directors
(1) Non-independent directors
Non-independent directors of the company are not entitled to director allowances.
Non-independent directors who receive remuneration from the company receive remuneration based on their specific positions and duties in the company, their ability to perform duties in actual work, and their role and contribution to the company.
(2) Independent directors
Allowance for independent directors of the company: RMB 72,000 per person per year (tax included).
- Senior management compensation plan
The company's senior managers comprehensively assess their remuneration based on their specific management positions in the company, actual work performance, and the company's operating performance and other factors.
- Specific salary standards
The remuneration structure of the company's directors and senior managers consists of basic remuneration, performance remuneration and medium- and long-term incentives. In principle, the proportion of performance remuneration shall not be less than 50% of the total basic salary and performance remuneration.
4. Other provisions
- The basic remuneration of non-independent directors and senior managers who receive remuneration from the company is paid by the company on a monthly basis; performance remuneration is determined by a comprehensive evaluation by the remuneration and assessment committee of the board of directors and authorized to be implemented by the chairman of the board. For those who hold multiple positions at the same time, corresponding remuneration will be paid based on the performance of the main position and the contribution of related positions.
A certain proportion of performance-based remuneration will be released after the disclosure of the annual report and performance evaluation. The specific deferred payment ratio will be determined by the Remuneration and Appraisal Committee of the Board of Directors. The remuneration and assessment committee of the company's board of directors will calculate it based on this system and the assessment results, and will be issued under the signature of the chairman of the company.
Allowances for independent directors are paid monthly.
If the company's directors and senior managers leave office due to reasons such as change of term, re-election, resignation during the term, etc., their remuneration will be calculated and paid based on their actual service time.
The above-mentioned remuneration is all tax-included income, and the personal income tax involved will be withheld and paid by the company.
If relevant stop-payment recourse is involved, the company shall comply with the remuneration system and shall not damage the company's legitimate rights and interests.
5. Salary recovery and payment suspension
- If any of the following circumstances occurs during the term of office of the company's directors or senior managers, the company has the right to cancel the payment of performance pay or allowances:
(1) Being publicly condemned or declared unfit to serve as a director or senior manager of a listed company by the Shenzhen Stock Exchange;
(2) Serious dereliction of duty or abuse of power;
(3) Seriously harming the company’s interests or causing significant economic losses to the company;
(4) Other major violations of laws and regulations.
When the company retrospectively restates its financial report due to financial fraud and other misstatements, the company will re-evaluate the performance compensation and medium- and long-term incentive income of directors and senior managers and recover the excess payment accordingly.
If directors or senior managers violate their obligations and cause losses to the listed company, or are at fault for financial fraud, misappropriation of funds, illegal guarantees and other illegal activities, the company will reduce or stop paying unpaid performance remuneration and medium- and long-term incentive income according to the severity of the case, and fully or partially recover the performance remuneration and medium- and long-term incentive income that have been paid during the period when the relevant behavior occurred.
Matters not covered in this plan shall be implemented in accordance with the provisions of national laws, administrative regulations, departmental rules, normative documents and the "Articles of Association"; if this plan conflicts with laws, administrative regulations, departmental rules, normative documents promulgated by the country in the future and the "Articles of Association" modified through legal procedures, the provisions of relevant laws, administrative regulations, departmental rules, normative documents and the "Articles of Association" shall be implemented.
This plan has been reviewed and approved at the second meeting of the company's ninth board of directors and still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
Board of Directors of Zhejiang Xianju Pharmaceutical Co., Ltd.
April 23, 2026